EPOR binds EPOR agonists

Stable Identifier
Reaction [binding]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. EPO binds to the erythropoietin receptor (EPOR) and triggers the JAK2/STAT5 signalling cascade which ultimately signals the activatation of nuclear target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. The inhibition of apoptosis is critical in erythroid differentiation. EPO also activates other intracellular proteins involved in erythroid cell proliferation and survival.

The PEGylated functional analogue of EPO (peginesatide) and recombinant EPO forms (the epoetins) are used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy and chemotherapy (Bennet et al. 2004, Singh et al. 2006, Besarab et al. 2012, Zabaneh et al. 2015, Fishbane & Shah 2015, Zadeh 2017)
Literature References
PubMed ID Title Journal Year
28142147 History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

Kalantar-Zadeh, K

Am J Nephrol 2017
24584613 Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis

El-Shahawy, M, Qiu, P, O'Neil, J, Runyan, G, Zabaneh, R, Roppolo, M, Roger, SD

Perit Dial Int 2015
15459301 Pure red-cell aplasia and epoetin therapy

Trifilio, SM, Klinge, SA, Kuzel, TM, Belknap, SM, McWilliams, N, Casadevall, N, Schumock, GT, Bennett, CL, McKoy, JM, Nissenson, AR, Raisch, DW, Tallman, MS, Luminari, S, Locatelli, F, Rossert, J, Evens, AM, Kim, B, Lyons, EA

N Engl J Med 2004
17108343 Correction of anemia with epoetin alfa in chronic kidney disease

CHOIR Investigators, -, Barnhart, H, Sapp, S, Szczech, L, Singh, AK, Tang, KL, Reddan, D, Wolfson, M

N Engl J Med 2006
22935486 An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients

Besarab, A, Mayo, M, Pergola, PE, Zeig, SN, Polu, KR, Schiller, B, Martin, ER, Francisco, CA, Whittier, FC, Zabaneh, RI, Duliege, AM

BMC Nephrol 2012
25582283 The emerging role of biosimilar epoetins in nephrology in the United States

Fishbane, S, Shah, HH

Am J Kidney Dis 2015
Orthologous Events
Cite Us!